NCT05958381Recruiting
Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation
Source: ClinicalTrials.gov · Last updated 15 Sept 2026
Brief summary (registry, in English)
The purpose of the study is to test whether low level electric stimulation, called transcranial Direct Current Stimulation (tDCS), on the part of the brain (i.e., presupplementary motor area) thought to aid in memory will improve verbal retrieval in multiple sclerosis patients. The primary outcome measures are neuropsychological assessments of verbal retrieval, and the secondary measures are neuropsychological assessments of other cognitive abilities and electroencephalography (EEG) measures. Additionally, the study will examine the degree to which baseline assessments of cognition and concussion history predict responses to treatment over time, both on assessments administered within the intervention period and at follow-up.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 14 Jul 2023
- Start date
- 18 Oct 2023
- Primary completion date
- 29 Jun 2027
- Lead sponsor
- The University of Texas at Dallas
- Diseases
- Multiple sclerosis
- NCT number
- NCT05958381
What you commit to
- Study type: Interventional
- Planned participants: 100
- From 18 Oct 2023 to the primary completion date, 29 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- º Relapse or acute MS exacerbation or a course of steroids in the two months preceding the testing
- present drug abuse
Other illness
- º Potentially confounding psychological or neurological disorder, including:
- dementia of any type
- epilepsy or other seizure disorders
- stroke
- Parkinson's disease
- Huntington's disease
- º inability to give informed consent
- º cranial implants
- º skull defects that affect tDCS administration
- º use of medications that interact with or potentially interact with tDCS effects, including:
Other
- º Participants using benzodiazepines must have been on a stable dose for at least two months
- severe traumatic brain injury
- brain tumor
- blood vessel abnormalities in the brain
- anti-convulsants
- L-dopa
- carbamazepine
- sulpiride
- pergolide
- lorazepam
- rivastigmine
- dextromethorphan
- D-cycloserine
- flunarizine
- ropinirole
- stimulants (dextroamphetamine/amphetamine/modafinil/armodafinil) must be stopped during enrollment
Who the study is looking for
- º Diagnosed with relapsing-remitting multiple sclerosis (RRMS)
- º Memory retrieval deficit based on neuropsychological testing done in our lab
- º Must be fluent in speaking and reading English.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The University of Texas at Dallas Coordinator of this site? Confirm its status | Richardson | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.